FDA requires stronger warnings about rare but serious incidents related to certain prescription insomnia medicines


The U.S. Food and Drug Administration announced the agency is requiring a new boxed warning – the agency’s most prominent warning – on certain prescription insomnia drugs to better ensure patients and their health care professionals have the information they need when considering use of these medicines.  The boxed warning follows several reports of rare, but serious injuries and deaths resulting from various complex sleep behaviors after taking these medicines.

Previous Article

HHS Report on Pain Management Best Practices: Updates, Gaps, Inconsistencies, and Recommendations

Next Article

Opioid Prescriptions to Teens, Young Adults Still Common